Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833192 | 1.00 | ALOX15 (0.41) | ALOX15BLMPMP22KMT2ADPP4 | |
| SCHEMBL1024050 | 0.82 | GABRR1 (0.36) | — | |
| SCHEMBL16195856 | 0.81 | — | — | |
| SCHEMBL14908934 | 0.80 | CHRM1 (0.35) | — | |
| SCHEMBL14908935 | 0.80 | CHRM1 (0.35) | — | |
| SCHEMBL1024531 | 0.79 | CPB2 (0.42) | — | |
| SCHEMBL18342421 | 0.78 | — | — | |
| SCHEMBL18342420 | 0.78 | — | — | |
| SCHEMBL3726149 | 0.77 | ACACB (0.30) | — | |
| SCHEMBL15238859 | 0.77 | CA2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188696-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | ALOX15 2745/4885BLM 1306/4885PMP22 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.